# The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients

> **NCT04108260** · PHASE4 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 5 (estimated)

## Conditions studied

- Hemophilia

## Interventions

- **DRUG:** Albutrepenonacog Alfa 1 UNT [IDELVION]

## Key facts

- **NCT ID:** NCT04108260
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-21
- **Primary completion:** 2021-11
- **Final completion:** 2022-04
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2020-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04108260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04108260, "The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04108260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*